Michael A. Carducci

54.6k citations

591 papers · 32.3k indexed · 8 hit papers · h-index 84

Impact in

Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
Cancer Research top 0.05%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics

Papers in

Pulmonary and Respiratory Medicine 388
- Prostate Cancer Treatment and Research 300
- Prostate Cancer Diagnosis and Treatment 91
- Renal cell carcinoma treatment 69
Oncology 238
- Cancer Treatment and Pharmacology 56
- Cancer Immunotherapy and Biomarkers 40

Co-authors: Mario A. Eisenberger Emmanuel S. Antonarakis Maha Hussain Robert Dreicer Роберто Пили Nicholas J. Vogelzang Samuel R. Denmeade Robert S. DiPaola
Journals: Journal of Clinical Oncology (220 papers)Clinical Cancer Research (19 papers)The Prostate (18 papers)Urology (16 papers)The Journal of Urology (15 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Michael A. Carducci

571 papers receiving 31.6k citations

Hit Papers

8 papers align trajectories log scale

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial 2018 · 695 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2017 Journal of Clinical Oncology
2016 Journal of Psychopharmacology
2015 JAMA Oncology
2015 New England Journal of Medicine
2011 The Lancet
2008 Journal of Clinical Oncology
2007 New England Journal of Medicine

Peers

Countries citing papers authored by Michael A. Carducci

Since Specialization

Citations

This map shows the geographic impact of Michael A. Carducci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Carducci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Carducci more than expected).

Fields of papers citing papers by Michael A. Carducci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Carducci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Carducci. The network helps show where Michael A. Carducci may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael A. Carducci, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael A. Carducci Line = papers co-authored together Michael A. Carducci links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data. Journal of Clinical Oncology ·Jérémie Calais, Vishnu Murthy, Andrew F. Voter, Kathleen Nguyen, Martin Allen-Auerbach, Sydney Caputo, Elisa M. Ledet, Opeoluwa Abraham Akerele, Abuzar Moradi Tuchayi, Courtney Lawhn-Heath, Michael A. Carducci, Martin G. Pomper, Channing J. Paller, Johannes Czernin, Lilja B. Sólnes, Thomas A. Hope, Oliver Sartor, Andrei Gafita	2024	1
2	Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). Journal of Clinical Oncology ·Christos E. Kyriakopoulos, Yu‐Hui Chen, Robert Jeraj, Fenghai Duan, Jun Luo, Emmanuel S. Antonarakis, Abhishek Tripathi, David Kosoff, Rohan Garje, Russell K. Pachynski, Rahul Atul Parikh, Andrea Harzstark, Nabil Adra, Benjamin L. Maughan, Yousef Zakharia, Paul G. Corn, Glenn Liu, Michael A. Carducci	2024	2
3	Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance) The Pharmacogenomics Journal ·Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Janey Wang, Flora Mulkey, William Kevin Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Michael A. Carducci, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Mark J. Ratain, Michael J. Morris, Howard L. McLeod	2024	0
4	Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data Journal of Nuclear Medicine ·Vishnu Murthy, Andrew F. Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen, Sydney Caputo, Elisa M. Ledet, Abraham Akerele, Abuzar Moradi Tuchayi, Courtney Lawhn-Heath, Tingchang Wang, Michael A. Carducci, Martin G. Pomper, Channing J. Paller, Johannes Czernin, Lilja B. Sólnes, Thomas A. Hope, Oliver Sartor, Jérémie Calais, Andrei Gafita	2024	4
5	2023 Kidney Cancer Research Summit Abstracts The Oncologist ·Georges Gebrael, Ged Mbbs, Irina Rifkind, Lori Tony, Keegan Daugherty, Amber Michalik, Hao Wang, Michael A. Carducci, Mark C. Markowski, Ed Reznik, Cerise Tang, Amy Xie, Eric Minwei Liu, Fengshen Kuo, Minsoo Kim, Mahdi Golkaram, Ying‐Bei Chen, Sounak Gupta	2023	1
6	ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations The Oncologist ·Georges Ged, Irina Rifkind, Lori Tony, Keegan Daugherty, Amber Michalik, Hao Wang, Michael A. Carducci, Mark C. Markowski	2023	7
7	The ENGAGE study: evaluation of a conversational virtual agent that provides tailored pre-test genetic education to cancer patients Journal of Cancer Survivorship ·Kala Visvanathan, Dana Petry, Michelle S. McCullough, Betty J. May, Ramkrishnan V. Tenkasi, Nitin Sharma, Catherine A. Klein, Angelisa Johnson, G. Killian, Melissa Camp, Channing J. Paller, Rima Couzi, Mary Wilkinson, Lisa K. Jacobs, Julie R. Lange, Danijela Jelovac, Michael A. Carducci, Mehran Habibi, Gauri Naik, Ashwin Kotwaliwale	2023	5
8	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Rahul Aggarwal, Alexander Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, Michael A. Carducci	2022	18
9	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) Clinical Cancer Research ·Роберто Пили, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto S. Fragomeni, Zsolt Szabó, Alan D. Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci	2017	76
10	Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer Cancer ·Brandon Bernard, Vinayak Muralidhar, Yu‐Hui Chen, Srikala S. Sridhar, Edith P. Mitchell, Curtis A. Pettaway, Michael A. Carducci, Paul L. Nguyen, Christopher J. Sweeney	2017	56
11	First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma Clinical Cancer Research ·Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez, Analía Azaro, Emiliano Calvo, Joan Seoane, Irene Braña, Elisabet Sicart, Ivelina Gueorguieva, Ann Cleverly, N. Sokalingum Pillay, D. Desaiah, Shawn T. Estrem, Luis Paz‐Ares, Matthias Holdhoff, Jaishri O. Blakeley, Michael Lahn, José Baselga	2014	200
12	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline Journal of Clinical Oncology ·Ethan Basch, D.A. Loblaw, Thomas K. Oliver, Michael A. Carducci, Ronald C. Chen, James N. Frame, Kristina Garrels, Sébastien J. Hotte, Michael W. Kattan, Derek Raghavan, Fred Saad, Mary-Ellen Taplin, Cindy Walker‐Dilks, J. Koudy Williams, Eric Winquist, Charles L. Bennett, Ted Wootton, R. Bryan Rumble, Stacie B. Dusetzina, Katherine S. Virgo	2014	165
13	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment Journal of Clinical Oncology ·Jeffrey S. Weber, Laura A. Levit, Peter C. Adamson, Suanna S. Bruinooge, Howard A. Burris, Michael A. Carducci, Adam P. Dicker, Mithat Gönen, Stephen J. O’Keefe, Michael A. Postow, Michael A. Thompson, David Waterhouse, Susan Weiner, Lynn M. Schuchter	2014	81
14	Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Andrew J. Armstrong, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, J.‐E. Damber, Laurence Belkoff, Örjan Nordle, G. Forsberg, Michael A. Carducci, Роберто Пили	2013	46
15	Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Journal of Clinical Oncology ·Роберто Пили, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Örjan Nordle, G. Forsberg, Michael A. Carducci, Andrew J. Armstrong	2011	161
16	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer Clinical Cancer Research ·Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia Creel, Kelly Mundy, S. L. Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, Michael A. Carducci	2010	62
17	Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo Molecular Cancer Therapeutics ·Madeleine S.Q. Kortenhorst, Sumit Isharwal, P. J. van Diest, Wasim H. Chowdhury, Cameron Marlow, Michael A. Carducci, Ronald Rodríguez, Robert W. Veltri	2009	31
18	Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy Journal of Clinical Oncology ·Milena Braga‐Basaria, Adrian S. Dobs, Denis C. Muller, Michael A. Carducci, Majnu John, Josephine M. Egan, Shehzad Basaria	2006	441
19	Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo Cancer Research ·Qinghua Xia, Jennifer Sung, Wasim H. Chowdhury, Chien-Lun Chen, Naseruddin Höti, Shabana Shabbeer, Michael A. Carducci, Ronald Rodríguez	2006	110
20	Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer Journal of Clinical Oncology ·Michael A. Carducci, Luna Musib, Merrill S. Kies, Роберто Пили, Mylene T. Truong, Julie R. Brahmer, Patricia E. Cole, Rana Sullivan, Jeanne R. Riddle, Jill Schmidt, Nathan Enas, Vikram Sinha, Donald Thornton, Roy S. Herbst	2006	150

About Michael A. Carducci

Michael A. Carducci is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism, having authored 591 papers that have together received 32.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (300 papers), Radiopharmaceutical Chemistry and Applications (114 papers), Prostate Cancer Diagnosis and Treatment (91 papers), Renal cell carcinoma treatment (69 papers), Cancer, Lipids, and Metabolism (65 papers), Cancer Treatment and Pharmacology (56 papers), Hormonal and reproductive studies (43 papers) and Cancer Immunotherapy and Biomarkers (40 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (17.4k citations), Cancer Research (6.8k citations), Oncology (11.4k citations), Radiology, Nuclear Medicine and Imaging (4.9k citations) and Hematology (1.8k citations). Michael A. Carducci has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Mario A. Eisenberger, Emmanuel S. Antonarakis, Maha Hussain, Robert Dreicer, Роберто Пили, Nicholas J. Vogelzang, Samuel R. Denmeade, Robert S. DiPaola, Yu‐Hui Chen and Glenn Liu. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Prostate, Urology and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact